TABLE 5.
Selected transcripts that were differentially regulated in infected versus uninfected DC from only one group of volunteers
| Category and gene symbol | Protein | Change in transcript levela in group:
|
|
|---|---|---|---|
| RR | PP | ||
| DC1 or DC maturation | |||
| CD38 | CD38 antigen (p45) | — | 73.3 |
| CCR7 | Chemokine (C-C motif) receptor 7 | — | 17.1 |
| CD58b | CD58 antigen (lymphocyte function-associated antigen 3) | — | 2.9 |
| LAMP3 | Lysosome-associated membrane protein 3 | — | 14.2 |
| GM-CSF | Colony-stimulating factor 2 (GM-CSF) | — | 50.4 |
| IL1F9 | IL-1 family, member 9 | 3.3 | — |
| IL7 | IL-7 | — | 2.2 |
| IL16 | IL-16 (lymphocyte chemoattractant factor) | — | −4.3 |
| IL18 | IL-18 (IFN-γ-inducing factor) | — | 14.6 |
| CASP1b | Caspase 1 (apoptosis-related cysteine protease) | — | 8.9 |
| IL23α | IL-23, alpha subunit p19 | 3.0 | — |
| IRF4 | IFN regulatory factor 4 | 2.5 | — |
| IRF1 | IFN regulatory factor 1 | 6.8 | — |
| Immunomodulatory | |||
| SOCS2 | Suppressor of cytokine signaling 2 | — | 5.5 |
| SOCS3 | Suppressor of cytokine signaling 3 | — | 30.0 |
| Signal transduction | |||
| STAT4 | Signal transducer and activator of transcription 4 | — | 23.5 |
| STAT1 | Signal transducer and activator of transcription 1 | 2.0 | — |
| Inhibition of maturation | |||
| LILRB1b | Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 1 | −2.0 | — |
| DCreg | |||
| CD200 | CD200 antigen | — | 38.8 |
| CD84 | CD84 antigen (leukocyte antigen) | — | −3.0 |
| INDO | Indoleamine-pyrrole 2,3-dioxygenase | — | 173.2 |
| IL10 | IL-10 | — | 7.4 |
| NOTCH2NL | Notch homolog 2 (Drosophila), N-terminal like | — | 2.5 |
| Proinflammatory | |||
| MIF | Macrophage MIF | 2.0 | — |
| TLR pathways | |||
| IRAK1BP1 | IL-1 receptor-associated kinase 1 binding protein 1 | — | 2.6 |
| TBK1 | Tank-binding kinase 1 | — | 2.0 |
| TLR1 | TLR1 | — | 3.5 |
| TRIF | TIR domain containing adaptor inducing IFN-β | — | 2.0 |
| IFN responsive | |||
| G1P3 | IFN, alpha-inducible protein (clone IFI-6-16) | — | 6.6 |
| IFI44 | IFN-induced protein 44 | — | 9.3 |
| IFIH1 | IFN induced with helicase C domain 1 | — | 3.3 |
| IFIT5 | IFN-induced protein with tetratricopeptide repeats 5 | — | 2.8 |
| IFITM1b | IFN-induced transmembrane protein 1 (9-27) | — | 18.4 |
| IFITM2 | IFN-induced transmembrane protein 2 (1-8D) | — | 7.0 |
| IFITM3 | IFN-induced transmembrane protein 3 (1-8U) | — | 10.0 |
| IFI44L | IFN-induced protein 44 | 9.1 | — |
| MNDA | Myeloid cell nuclear differentiation antigen | −2.5 | — |
| Antigen presentation | |||
| CD1D | CD1D antigen, d polypeptide | — | −13.1 |
| HLA-B | MHC, class I, B | — | 2.7 |
| HLA-DQα1 | MHC, class II, DQ alpha 1 | — | 3.0 |
| HLA-DMα | MHC, class II, DM alpha | — | −3.1 |
| HLA-DMβ | MHC, class II, DM beta | — | −11.2 |
| HLA-F | MHC, class I, F | — | 3.1 |
| HM13 | Histocompatibility (minor) 13 | — | −2.1 |
a
Values are fold changes in transcript levels between infected and uninfected tissue (P < 0.05). —, not significantly different between infected and uninfected tissue.
b
Transcript detected by multiple probe sets; values shown are from the probe set that had the largest fold change for one of the groups.